NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Rare Tumors and Cancer Predisposition in Individuals and Families

Recruiting

Conditions: Cancer
Hereditary Neoplasms
Genetic Predisposition to Cancer
Environment

First Posted Date: 2022-04-28

Last Posted Date: 2025-04-29

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 500

Registration Number: NCT05350761

Locations: 🇺🇸
NIH National Cancer Institute - Shady Grove, Rockville, Maryland, United States
🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Comprehensive Molecular and Clinical Evaluation of Pediatric and Adult MDS

Recruiting

Conditions: Myelodysplastic Syndromes

First Posted Date: 2022-04-28

Last Posted Date: 2025-04-06

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 1100

Registration Number: NCT05350748

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Testing Atezolizumab With Selinexor in People ≥ 12 Years Old With Alveolar Soft Part Sarcoma, The AXIOM Trial

Phase 2

Recruiting

Conditions: Advanced Alveolar Soft Part Sarcoma
Advanced Soft Tissue Sarcoma
Metastatic Alveolar Soft Part Sarcoma
Refractory Alveolar Soft Part Sarcoma
Unresectable Alveolar Soft Part Sarcoma

Interventions: Biological: Atezolizumab
Procedure: Biopsy Procedure
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Procedure: Echocardiography Test
Drug: Selinexor

First Posted Date: 2022-04-19

Last Posted Date: 2025-04-30

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 27

Registration Number: NCT05333458

Locations: 🇺🇸
Smilow Cancer Hospital Care Center at Saint Francis, Hartford, Connecticut, United States
🇺🇸
Yale University, New Haven, Connecticut, United States
🇺🇸
Keck Medicine of USC Koreatown, Los Angeles, California, United States

and more 8 locations

Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies

Phase 1

Recruiting

Conditions: Hematologic Neoplasms

Interventions: Procedure: donor lymphocyte infusion
Drug: Cyclophosphamide
Drug: Busulfan
Drug: Mycophenolate mofetil
Drug: Fludarabine
Drug: Sirolimus

First Posted Date: 2022-04-14

Last Posted Date: 2025-04-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 430

Registration Number: NCT05327023

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial

Phase 2

Recruiting

Conditions: Advanced Malignant Solid Neoplasm
Metastatic Malignant Solid Neoplasm
Unresectable Malignant Solid Neoplasm

Interventions: Drug: BET Bromodomain Inhibitor ZEN-3694
Procedure: Biopsy Procedure
Procedure: Biospecimen Collection
Procedure: Diagnostic Imaging Testing
Drug: Talazoparib

First Posted Date: 2022-04-14

Last Posted Date: 2025-05-16

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 88

Registration Number: NCT05327010

Locations: 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸
City of Hope at Irvine Lennar, Irvine, California, United States
🇺🇸
UC San Diego Moores Cancer Center, La Jolla, California, United States

and more 32 locations

Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation

Phase 2

Active, not recruiting

Conditions: Stage III Colon Cancer AJCC v8
Metastatic Colon Adenocarcinoma
Stage III Rectal Cancer AJCC v8
Stage IV Colon Cancer AJCC v8
Unresectable Colon Adenocarcinoma
Metastatic Rectal Adenocarcinoma
Stage IV Rectal Cancer AJCC v8
Unresectable Rectal Adenocarcinoma

Interventions: Biological: Cetuximab
Drug: Encorafenib
Biological: Nivolumab

First Posted Date: 2022-04-04

Last Posted Date: 2025-04-06

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 84

Registration Number: NCT05308446

Locations: 🇺🇸
Henry Ford Health Warren Hospital, Warren, Michigan, United States
🇺🇸
Henry Ford Saint John Hospital - Van Elslander, Grosse Pointe Woods, Michigan, United States
🇺🇸
CTCA at Western Regional Medical Center, Goodyear, Arizona, United States

and more 283 locations

Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy

Phase 2

Withdrawn

Conditions: Platinum-Refractory Fallopian Tube Carcinoma
Platinum-Refractory Ovarian Carcinoma
Platinum-Refractory Primary Peritoneal Carcinoma
Recurrent Platinum-Resistant Fallopian Tube Carcinoma
Recurrent Primary Peritoneal Endometrioid Adenocarcinoma
Recurrent Fallopian Tube Endometrioid Adenocarcinoma
Recurrent Fallopian Tube High Grade Serous Adenocarcinoma
Recurrent Platinum-Resistant Ovarian Carcinoma
Recurrent Ovarian Endometrioid Adenocarcinoma
Recurrent Ovarian High Grade Serous Adenocarcinoma

Interventions: Procedure: Computed Tomography
Procedure: Magnetic Resonance Imaging
Drug: Copanlisib Hydrochloride
Drug: Paclitaxel
Drug: Olaparib
Drug: Pegylated Liposomal Doxorubicin Hydrochloride
Drug: Topotecan Hydrochloride

First Posted Date: 2022-03-25

Last Posted Date: 2023-09-26

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT05295589

Locations: 🇺🇸
Cleveland Clinic Foundation, Cleveland, Ohio, United States
🇺🇸
University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa, United States
🇺🇸
University of Colorado Hospital, Aurora, Colorado, United States

and more 2 locations

Effect of Ultra-processed Versus Unprocessed Diets on Energy Metabolism

Not Applicable

Recruiting

Conditions: Healthy Diet
Obesity

Interventions: Other: Ultra-processed food, high energy density
Other: Ultra-processed food, both low
Other: Ultra-processed food, both high
Other: Unprocessed food diet

First Posted Date: 2022-03-22

Last Posted Date: 2025-05-04

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 200

Registration Number: NCT05290064

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Olaparib in Subjects With Advanced Pancreatic Acinar Cell Carcinoma

Phase 2

Active, not recruiting

Conditions: Pancreatic Acinar Cell Carcinoma

Interventions: Drug: Olaparib

First Posted Date: 2022-03-18

Last Posted Date: 2025-04-02

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 20

Registration Number: NCT05286827

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma

Phase 2

Recruiting

Conditions: Intrahepatic Cholangiocarcinoma (Icc)
Colorectal Cancer
Colorectal Neoplasms
Cholangiocarcinoma
Bile Duct Cancer
Metastatic Colorectal Cancer (Mcrc)
Intrahepatic Bile Duct Cancer
Bile Duct Neoplasms

Interventions: Drug: Floxuridine
Drug: 5-Fluorouracil
Drug: Irinotecan
Device: Intera 3000 Hepatic Artery Infusion Pump (HAIP)
Drug: Oxaliplatin
Drug: Leucovorin
Drug: PDS01ADC
Drug: Dexamethasone
Drug: Gemcitabine

First Posted Date: 2022-03-18

Last Posted Date: 2025-04-15

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 48

Registration Number: NCT05286814

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Home Terms & Conditions Privacy Policy